Pharmaceuticals Japan

Japan Viral Vector Manufacturing Market Analysis, 2024–2034

Japan Viral Vector Manufacturing Market Industry Trends and Forecast to 2034: Segmented by (Vector, Scale, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $113.4 Mn Estimated value
Estimate 2025 $136.2 Mn 5.9% of the global market
Projected 2034 $707.9 Mn 419.9% Adds $571.7 Mn over 9 forecast years
CAGR 2025–2034 20.1% Faster than 85% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Japan is 5.91% of the global market.
  • In APAC, the largest is China at $217.8 Mn.
  • Fastest growing: India at 23% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$571.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Viral Vector Manufacturing Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $113.4 Mn — —
2025 (base) $136.2 Mn +$22.8 Mn —
2026 (forecast) $163.5 Mn +$27.4 Mn +20.1%
2027 (forecast) $196.4 Mn +$32.9 Mn +44.2%
2028 (forecast) $235.9 Mn +$39.5 Mn +73.2%
2029 (forecast) $283.3 Mn +$47.4 Mn +108.1%
2030 (forecast) $340.2 Mn +$56.9 Mn +149.9%
2031 (forecast) $408.6 Mn +$68.4 Mn +200.1%
2032 (forecast) $490.7 Mn +$82.1 Mn +260.4%
2033 (forecast) $589.4 Mn +$98.6 Mn +332.9%
2034 (forecast) $707.9 Mn +$118.5 Mn +419.9%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.30 Bn
  2. North America $1.17 Bn
  3. US $1.01 Bn
  4. Europe $454.0 Mn
  5. APAC $429.2 Mn
  6. China $217.8 Mn
  7. Canada $172.4 Mn
  8. Japan (this report) $136.2 Mn
  9. Latin America $100.5 Mn
  10. Middle East $81.8 Mn
  11. Germany $76.1 Mn
  12. France $65.6 Mn
  13. UK $59.2 Mn
  14. Italy $57.6 Mn
  15. Brazil $52.3 Mn
  16. Spain $44.7 Mn
  17. Saudi Arabia $45.2 Mn
  18. India $44.8 Mn
  19. Ecuador $41.8 Mn
  20. Africa $37.3 Mn
  21. Mexico $35.4 Mn
  22. Australia $26.7 Mn
  23. New Zealand $24.9 Mn
  24. Russia $21.5 Mn
  25. South Africa $17.2 Mn
  26. UAE $10.3 Mn
  27. Egypt $6.2 Mn
  28. Philippines $4.5 Mn
  29. Hong Kong $4.3 Mn
  30. Malaysia $3.8 Mn
  31. Singapore $2.9 Mn
  32. Thailand $2.8 Mn
  33. Kenya $1.5 Mn

The Japan Viral Vector Manufacturing Market Analysis Executive Summary

Viral vector manufacturing makes the AAV, lentiviral and other vectors that carry genes in gene and cell therapies.

Key segments of the viral Vector Manufacturing market include vector (AAV, Lentivirus and Adenovirus) and scale (Clinical and Commercial).

Japan Viral Vector Manufacturing Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the viral Vector Manufacturing market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the viral Vector Manufacturing market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the viral Vector Manufacturing market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Viral Vector Manufacturing Market in Japan

The viral Vector Manufacturing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Viral Vector Manufacturing Market in Japan

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for viral Vector Manufacturing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Viral Vector Manufacturing right now, from free public sources.

Latest research 30 papers since 2021 (worldwide)

  1. Continuous Capture of Recombinant Adeno-Associated Virus Particles Using Twin-Column CaptureSMB. Biotechnology and bioengineering, 2026
  2. Comparison of Wildtype and Recombinant Adeno-Associated Virus (AAV) Production Reveals Distinct Productivity and Content Ratio Profiles. Biotechnology journal, 2026
  3. Clinical evidence on non-viral CAR-T cell therapies for solid tumors: a scoping review. Frontiers in immunology, 2026
  4. CQV Considerations for Single-Use Systems in Biopharmaceutical Manufacturing: A Practical Framework. PDA journal of pharmaceutical science and technology, 2026
  5. Suspension-Adapted HEK293FT Cells Enable High-Density Transfection for Efficient Lentiviral Vector Production in CAR-T Therapy. Bioengineering (Basel, Switzerland), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Viral Vector Manufacturing in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How much research is published on Viral Vector Manufacturing?
PubMed lists 30 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Viral Vector Manufacturing in Japan? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on drug development and manufacturing and cell and gene therapy

See the topic